US5245047A
(en)
*
|
1988-02-22 |
1993-09-14 |
Warner-Lambert Company |
Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
|
JP3171931B2
(ja)
*
|
1992-06-02 |
2001-06-04 |
高砂香料工業株式会社 |
(R)−(−)−4−シアノ−3−ヒドロキシ酪酸t−ブチルエステル及びその製造方法
|
US5298627A
(en)
*
|
1993-03-03 |
1994-03-29 |
Warner-Lambert Company |
Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
|
GB9512837D0
(en)
*
|
1995-06-23 |
1995-08-23 |
Zeneca Ltd |
reduction of ketone groups
|
HRP960312B1
(en)
|
1995-07-17 |
2001-10-31 |
Warner Lambert Co |
NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
|
US6087511A
(en)
*
|
1996-07-16 |
2000-07-11 |
Warner-Lambert Company |
Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
|
US5908953A
(en)
*
|
1996-12-18 |
1999-06-01 |
Mitsubishi Chemical Corporation |
Method for producing (R)-4-cyano-3-hydroxybutyric acid lower alkyl ester
|
JPH11171850A
(ja)
*
|
1997-12-12 |
1999-06-29 |
Kanegafuchi Chem Ind Co Ltd |
酪酸エステル誘導体の製造方法
|
KR100681366B1
(ko)
*
|
1997-12-19 |
2007-02-12 |
워너-램버트 익스포트 리미티드 |
1,3-디올의 합성방법
|
CA2329893A1
(en)
*
|
1998-04-30 |
1999-11-11 |
Kaneka Corporation |
Process for producing 6-cyanomethyl-1,3-dioxane-4-acetic acid derivatives
|
JP3803551B2
(ja)
|
1998-08-05 |
2006-08-02 |
株式会社カネカ |
光学活性2−[6−(ヒドロキシメチル)−1,3−ジオキサン−4−イル]酢酸誘導体の製造法
|
KR100313668B1
(ko)
*
|
1999-02-03 |
2001-11-26 |
박영구 |
(r)-4-시아노-3-히드록시부티르산 에스테르의 제조방법
|
HU227840B1
(en)
*
|
1999-05-06 |
2012-05-02 |
Egis Gyogyszergyar Nyilvanosan M Kod Ruszvunytarsasag |
Intermediates of atorvastatin synthesis and process for producing them
|
CA2339357A1
(en)
*
|
1999-06-04 |
2000-12-14 |
Kenji Inoue |
Processes for the preparation of 5-hydroxy-3-oxopentanoic acid derivatives
|
US20040063969A1
(en)
*
|
1999-10-18 |
2004-04-01 |
Egis Gyogyszergyar Rt. |
Process for the preparation of amorphous atorvastatin calcium
|
WO2001044181A1
(en)
|
1999-12-17 |
2001-06-21 |
Warner Lambert Research And Development Ireland Limited |
A process for producing crystalline atorvastatin calcium
|
MXPA02004078A
(es)
|
1999-12-17 |
2002-10-11 |
Warner Lambert Res & Dev |
Un proceso a escala industrial para producir sal de hemi calcio de trihidrato de atorvastatin cristalino.
|
CN100368386C
(zh)
*
|
2000-05-31 |
2008-02-13 |
中国医学科学院药物研究所 |
(±)对氟-2-(2-甲基-丙酰基)-4-氧-n,3-二苯基-苯丁酰胺的合成方法以及其中的中间体
|
CN101250133B
(zh)
*
|
2000-05-31 |
2010-06-09 |
中国医学科学院药物研究所 |
(±)对氟-2-(2-甲基-丙酰基)-4-氧-n,3-二苯基-苯丁酰胺的合成方法以及其中的中间体
|
US6476235B2
(en)
|
2001-01-09 |
2002-11-05 |
Warner-Lambert Company |
Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide
|
EP1728785A1
(en)
|
2001-01-09 |
2006-12-06 |
Warner-Lambert Company LLC |
7-[(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-phenylcarbamoyl-pyrrol-1-yl]-heptanoic acid ester 3,5-dioxo-acetal
|
WO2002057229A1
(en)
*
|
2001-01-19 |
2002-07-25 |
Biocon India Limited |
FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
|
SI20814A
(sl)
*
|
2001-01-23 |
2002-08-31 |
LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. |
Priprava amorfnega atorvastatina
|
SI20848A
(sl)
|
2001-03-14 |
2002-10-31 |
Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. |
Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
|
CZ20033478A3
(cs)
*
|
2001-06-29 |
2004-10-13 |
Warner@Lambertácompanyállc |
Krystalické formy vápenaté soli }@�B [R@}RgŹRgB]@}@fluorofenylB@betaŹ@delta@dihydroxy@Q@}�@methylethylB@fenyl[}fenylaminoBkarbonyl]@�H@pyrrol@�@heptanové kyseliny }atorvastatinB
|
SK792004A3
(sk)
|
2001-07-06 |
2005-03-04 |
Teva Pharmaceutical Industries Ltd. |
Syntéza a medziprodukty derivátov 3,5-dihydroxyheptánovej kyseliny
|
EP1404639A1
(en)
|
2001-07-06 |
2004-04-07 |
Ciba SC Holding AG |
Process for the preparation of intermediates useful in the synthesis of statin derivatives especially 7-amino 3,5-dihydroxy heptanoic acid derivatives, and intermediates thereof
|
IL159719A0
(en)
*
|
2001-07-06 |
2004-06-20 |
Teva Pharma |
Process for the preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives via 6-cyano syn 3,5-dihydroxy hexanoic acid derivatives
|
WO2003011826A1
(en)
|
2001-07-30 |
2003-02-13 |
Dr. Reddy's Laboratories Ltd. |
Crystalline forms vi and vii of atorvastatin calcium
|
JP4765217B2
(ja)
*
|
2001-07-30 |
2011-09-07 |
住友化学株式会社 |
(r)−4−シアノ−3−ヒドロキシブタン酸エステルの製造法
|
PE20030324A1
(es)
*
|
2001-07-31 |
2003-04-03 |
Warner Lambert Co |
Composiciones farmaceuticas de amlodipina y atorvastatina
|
US7563911B2
(en)
*
|
2001-08-31 |
2009-07-21 |
Morepen Laboratories Ltd. |
Process for the preparation of amorphous atorvastin calcium salt (2:1)
|
UA77990C2
(en)
*
|
2001-12-12 |
2007-02-15 |
|
Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid
|
KR100849880B1
(ko)
*
|
2001-12-20 |
2008-08-01 |
주식회사 중외제약 |
광학활성 2-[6-(치환된 알킬)-1,3-디옥산-4-일]아세트산유도체의 신규 제조 방법
|
CZ296967B6
(cs)
|
2002-02-01 |
2006-08-16 |
Zentiva, A.S. |
Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu)
|
DE10212492B4
(de)
*
|
2002-03-21 |
2012-02-02 |
Daimler Ag |
Kolbenpumpe
|
ES2287549T3
(es)
*
|
2002-08-06 |
2007-12-16 |
Warner-Lambert Company Llc |
Procedimiento para preparar la fenilamida del acido 5-(4-fluorofenil)-1-(2-((2r,4r)-4-hidroxi-6-oxo-tetrahidropiran-2-il)etil)-2-isopropil-4-fenil-1h-pirrol-3-carboxilico.
|
DE60336324D1
(de)
*
|
2002-08-09 |
2011-04-21 |
Codexis Inc |
Enzymatische verfahren zur herstellung 4-substituierter 3-hydroxybuttersäure-derivate
|
CA2491051A1
(en)
*
|
2002-09-03 |
2004-03-18 |
Morepen Laboratories Limited |
Atorvastatin calcium form vi or hydrates thereof
|
HRP20020885B1
(en)
*
|
2002-11-11 |
2007-05-31 |
GlaxoSmithKline istra�iva�ki centar Zagreb d.o.o. |
SUBSTITUTED 9a-N-{N'-[4-(SULFONYL)PHENYLCARBAMOYL]}DERIVATIVES 9-DEOXO-9-DIHYDRO-9a-AZA-9a-HOMOERITHROMYCIN A AND 5-O-DESOZAMINYL-9-DEOXO-9-DIHYDRO-9a-AZA-9a-HOMOERITHRONOLIDE A
|
EP1615883A1
(en)
*
|
2003-04-14 |
2006-01-18 |
Warner-Lambert Company |
Process for preparing 5-(4-fluorophenyl)-1-[2-((2r,4r)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1h-pyrrole-3-carboxylic acid phenylamide
|
US20040248972A1
(en)
*
|
2003-05-16 |
2004-12-09 |
Ambit Biosciences Corporation |
Compounds and uses thereof
|
AU2004247023A1
(en)
*
|
2003-05-16 |
2004-12-23 |
Ambit Biosciences Corporation |
Heterocyclic compounds and uses thereof
|
US20050182125A1
(en)
*
|
2003-05-16 |
2005-08-18 |
Ambit Biosciences Corporation |
Pyrrole compounds and uses thereof
|
US7790197B2
(en)
*
|
2003-06-09 |
2010-09-07 |
Warner-Lambert Company Llc |
Pharmaceutical compositions of atorvastatin
|
US20040253305A1
(en)
*
|
2003-06-12 |
2004-12-16 |
Luner Paul E. |
Pharmaceutical compositions of atorvastatin
|
US7655692B2
(en)
*
|
2003-06-12 |
2010-02-02 |
Pfizer Inc. |
Process for forming amorphous atorvastatin
|
US20050271717A1
(en)
*
|
2003-06-12 |
2005-12-08 |
Alfred Berchielli |
Pharmaceutical compositions of atorvastatin
|
CN1852894A
(zh)
*
|
2003-09-17 |
2006-10-25 |
沃尼尔·朗伯有限责任公司 |
[R-(R*, R*)]-2-(4-氟苯基) -β,δ-二羟基-5-(1-甲基乙基) -3-苯基-4-[(苯基氨基)羰基] -1 H-吡咯-1-庚酸的结晶形式
|
AU2003272080A1
(en)
*
|
2003-09-18 |
2005-04-06 |
Biocon Limited |
Novel process for the preparation of tert-butyl 6-cyano-5-hydroxy-3-oxohexanoate
|
JP2007517028A
(ja)
*
|
2003-12-29 |
2007-06-28 |
レツク・フアーマシユーテイカルズ・デー・デー |
非晶質の(4r−シス)−6−[2−[3−フェニル−4−(フェニルカルバモイル)−2−(4−フルオロフェニル)−5−(1−メチルエチル)−ピロール−1−イル]−エチル]−2,2−ジメチル−[1,3]−ジオキサン−4−イル−酢酸を調製する方法
|
CA2456430A1
(en)
*
|
2004-01-28 |
2005-07-28 |
Brantford Chemicals Inc. |
Improved process for the preparation of amorphous atorvastatin calcium
|
EP1727795B1
(en)
|
2004-03-17 |
2012-02-15 |
Ranbaxy Laboratories Limited |
Process for the production of atorvastatin calcium in amorphous form
|
CA2562844A1
(en)
*
|
2004-04-16 |
2005-10-27 |
Pfizer Products Inc. |
Process for forming amorphous atorvastatin calcium
|
CA2649054A1
(en)
|
2004-05-05 |
2005-11-10 |
Pfizer Products Inc. |
Salt forms of [r-(r*,r*)]-2-(4-fluorophenyl)-.beta., .delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid
|
ES2586561T3
(es)
*
|
2004-07-16 |
2016-10-17 |
Lek Pharmaceuticals D.D. |
Productos de degradación oxidativa de atorvastatina calcio
|
MX2007000765A
(es)
|
2004-07-20 |
2007-03-28 |
Warner Lambert Co |
Formas cristalinas de sal de calcio del acido (r-(r*, r*))-2- (4-fluorofenil)- beta,gama- dihidroxi-5- (1-metiletil)-3 -fenil-4-((fenilamino) (carbonil)-1ih -pirrol-1- heptanoico (2:1).
|
WO2006021969A1
(en)
*
|
2004-08-27 |
2006-03-02 |
Biocon Limited |
Process for atorvastatin calcium amorphous
|
MX2007004722A
(es)
*
|
2004-10-28 |
2007-06-15 |
Warner Lambert Co |
Procedimiento para formar atorvastatina amorfa.
|
CA2588216A1
(en)
|
2004-11-22 |
2006-05-26 |
Dexcel Pharma Technologies Ltd. |
Stable atorvastatin formulations
|
EP1819319A1
(en)
*
|
2004-12-02 |
2007-08-22 |
Warner-Lambert Company LLC |
Pharmaceutical compositions of amorphous atorvastatin and process for preparing same
|
JP2009507821A
(ja)
*
|
2005-09-09 |
2009-02-26 |
ファイザー・サイエンス・アンド・テクノロジー・アイルランド・リミテッド |
アトルバスタチン中間体の調製
|
JP2009507822A
(ja)
*
|
2005-09-09 |
2009-02-26 |
ファイザー・サイエンス・アンド・テクノロジー・アイルランド・リミテッド |
アトルバスタチン中間体の調製
|
US20090216029A1
(en)
*
|
2005-09-16 |
2009-08-27 |
Yatendra Kumar |
Process for the production of atorvastatin calcium in amorphous form
|
CA2547216A1
(en)
|
2005-09-21 |
2007-03-21 |
Renuka D. Reddy |
Process for annealing amorphous atorvastatin
|
PT1957452E
(pt)
|
2005-11-21 |
2010-05-25 |
Warner Lambert Co |
Novas formas de ácido [r-(r*,r*)]-2-(4-fluorofenil)-b,b--di-hidroxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)-carbonil]-1h-pirrole-1-heptanóico magnésico
|
EP1810667A1
(en)
|
2006-01-20 |
2007-07-25 |
KRKA, tovarna zdravil, d.d., Novo mesto |
Pharmaceutical composition comprising amorphous atorvastatin
|
WO2008042876A2
(en)
|
2006-10-02 |
2008-04-10 |
Codexis, Inc. |
Compositions and methods for producing stereoisomerically pure statins and synthetic intermediates therefor
|
WO2008053312A2
(en)
*
|
2006-11-02 |
2008-05-08 |
Cadila Pharmaceuticals Limited |
Process for preparing amorphous atorvastatin hemi calcium salt and its intermediate
|
WO2008059366A2
(en)
*
|
2006-11-17 |
2008-05-22 |
Pfizer Products Inc. |
Process for the preparation of cis-1, 3-diols from the corresponding beta-hydroxy ketones employing microbial ketone reductases
|
US7834195B2
(en)
*
|
2007-01-24 |
2010-11-16 |
Apotex Pharmachem Inc. |
Atorvastatin calcium propylene glycol solvates
|
US20110142883A1
(en)
*
|
2007-07-20 |
2011-06-16 |
Actavis Group Ptc Ehf |
Amorphous Coprecipitates of Atorvastatin Pharmaceutically Acceptable Salts
|
ES2523304T3
(es)
|
2007-08-03 |
2014-11-24 |
Pfizer Products Inc. |
Procedimiento de preparación de compuestos quirales
|
EP2075246A1
(en)
|
2007-12-27 |
2009-07-01 |
M. J. Institute of Research |
A process for preparation of amorphous form of atorvastatin hemi-calcium salt
|
US8115015B2
(en)
*
|
2009-01-26 |
2012-02-14 |
Cadila Healthcare Limited |
Process for the preparation of amorphous atorvastatin calcium
|
GB2474687A
(en)
|
2009-10-23 |
2011-04-27 |
Phoenix Chemicals Ltd |
A continuous process for the production of (R)-6-cyano-5-hydroxy-3-oxo-hexanoic acid tert-butyl ester (and derivatives)
|
KR20120011249A
(ko)
|
2010-07-28 |
2012-02-07 |
주식회사 경보제약 |
아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
|
EP2614057B1
(en)
*
|
2010-09-09 |
2015-10-21 |
DSM Sinochem Pharmaceuticals Netherlands B.V. |
Salts of 7-amino-3,5-dihydroxyheptanoic acid esters
|
CN103702982A
(zh)
|
2011-07-01 |
2014-04-02 |
中化帝斯曼制药有限公司荷兰公司 |
阿托伐他汀半钙的超细晶体
|
CN102766072B
(zh)
*
|
2012-08-07 |
2013-12-25 |
浙江宏元药业有限公司 |
一种制备阿托伐他汀钙手性侧链的方法
|
CN103145584B
(zh)
*
|
2013-03-05 |
2015-08-26 |
复旦大学 |
一种合成(3r,5r)-3,5-二羟基-6-氰基己酸酯的方法
|
CN106397241A
(zh)
*
|
2016-08-23 |
2017-02-15 |
杨锋 |
一种4‑甲基‑3‑氧代‑n‑苯基戊酰胺的绿色环保后处理方法
|
CN108033899B
(zh)
*
|
2017-12-06 |
2020-04-10 |
浙江科技学院 |
一种(r)-6-氰基-5-羟基-3-羰基己酸叔丁酯的制备方法
|